Pfizer seeking spot in China’s private insurance catalog, Bloomberg reports

Western drugmakers, including Eli Lilly (LLY), Pfizer (PFE), and Novo Nordisk (NVO), are looking to boost sales of their most innovative and expensive medicines in China, the world’s second-largest pharmaceuticals market, by trying to get their treatments included in Beijing’s new catalog for commercial health insurance, Bloomberg’s Amber Tong reports. A total of 121 drugs, including blockbuster medicines and treatments for rare diseases, have cleared the initial screening for the catalog, according to the report.